tildrakizumab is a monoclonal antibody designed for the treatment of immunologically mediated inflammatory disorders
tildrakizumab was designed to block interleukin-23 a cytokine that plays an important role in managing the immune system and autoimmune disease originally developed by schering-plough this drug is now part of merck's clinical program following that company's acquisition of schering-plough
sun pharmaceutical acquired worldwide rights to tildrakizumab for use in all human indications from merck in exchange for an upfront payment of u.s $80 million upon product approval sun pharmaceutical will be responsible for regulatory activities including subsequent submissions pharmacovigilance post approval studies manufacturing and commercialization of the approved product
as of march 2014 the drug was in phase iii clinical trials for plaque psoriasis the two trials will enroll a total of nearly 2000 patients and preliminary results are expected in june 2015
== see also ==
ustekinumab a monoclonal antibody targeting both il-12 and il-23 and used to treat plaque psoriasis launched in the united states under the brand name stelara
guselkumab another experimental il-23-specific monoclonal antibody
== references ==
^ statement on a nonproprietary name adopted by the usan council - tildrakizumab american medical association
^ http://www.merck.com/licensing/our-partnership/sunpharma_partnership.html
^ http://clinicaltrials.gov/ct2/show/nct01729754?term=sch-900222&phase=2&fund=2&rank=1
^ http://clinicaltrials.gov/ct2/show/nct01722331?term=sch-900222&phase=2&fund=2&rank=2
